A5059001742- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Asthma and respiratory diseases
- Autoimmune Bullous Skin Diseases
- Biosimilars and Bioanalytical Methods
- Allergic Rhinitis and Sensitization
- Hepatitis Viruses Studies and Epidemiology
- Vitamin D Research Studies
- Contact Dermatitis and Allergies
- RNA regulation and disease
- Dupuytren's Contracture and Treatments
- Cutaneous Melanoma Detection and Management
- Hepatitis B Virus Studies
- Genetic and rare skin diseases.
IRCCS Humanitas Research Hospital
2022-2025
University of Pavia
2021
Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It approved for treatment of moderate-to-severe plaque psoriasis. We conducted 52-week monocentric retrospective study to evaluate the effectiveness and safety risankizumab in real-life setting. Our included 131 adults with psoriasis all treated at least 52 weeks. Patient characteristics PASI (Psoriasis Area Severity Index) each visit were recorded. The percentages patients achieving 75%/90%/100% (PASI...
The management of plaque psoriasis that affects difficult-to-treat areas can be challenging. Biologics have become the treatment choice for moderate-to-severe psoriasis. However, there are limited data on their efficacy in sites (including scalp, palms/soles, nails and genitalia). We conducted a 52-week retrospective study to evaluate effectiveness risankizumab 202 patients with involvement at least one area. One hundred sixty-five had scalp psoriasis, 21 palms or soles, 72 were affected by...
Janus kinase (JAK) inhibitors are widely used for treating atopic dermatitis (AD) and alopecia areata (AA). Weight gain is an emergent adverse event associated with JAK inhibitors, particularly those acting on the JAK2 pathway. We conducted a retrospective monocentric 2-cohort study, including 226 patients, to evaluate prevalence of weight in patients AD AA who were treated at least one year. included 142 JAK1/2 cohort (receiving upadacitinib 30 mg or baricitinib 4 mg) 84 JAK1 15 abrocitinib...
There are no strong data regarding the treatment with biologics (especially for most recent anti-IL-17 and anti-IL-23 drugs) of patients psoriasis concomitant viral hepatitis. We assessed safety biologic drugs in who seropositive hepatitis B or C did not receive antiviral prophylaxis. conducted a retrospective single-center study. The efficacy treatments was evaluated by assessing Psoriasis Area Severity Index (PASI) score during all visits, minimum follow-up 52 weeks. All were hepatologist...
The treatment of moderate-to-severe atopic dermatitis (AD) in the elderly population could be challenging due to their comorbidities and side effects conventional systemic drugs.
Psoriasis is a chronic skin disease driven by immune system dysfunction and associated with increased cardiovascular risk metabolic disorders. Risankizumab an anti-interleukin-23 humanized monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis.